Our group requests continuation of funding 1. To permit the continuation of our participation in ECOG activities. 2. To develop and participate in Phase I and Phase II protocols through the ECOG program. 3. Extend group activities of Phase III human studies. Our accrual from 6/01/80 to 4/30/84 is 412 cases with 132 cases in the past year. 4. Continue to influence the very favorable accrual of cases into the existing surgical adjuvant ECOG protocols. Two surgical adjuvant protocols in colorectal cancer are chaired by our P.I. (EST 2276 and 4276). Protocol 2276 was terminated on 8/15/78 after a total accrual of 866 cases. Four hundred fifty-four cases are still alive on active follow-up. Protocol 4276 was closed after an accrual of 307 cases, but it remains blinded until the last patient entered has completed his treatment. 5. Support the development of primary surgical and surgical adjuvant protocols using multimodality approaches to therapy. Protocol 3282-""""""""Phase III combined modality therapy following resection of colrectal carcinoma in patients with nonmeasurable intra-abdominal metastases"""""""", chaired by Dr. Mansour was activated. Accrual to date is 101 cases. 6. Promote the growth of the Surgical Committee of ECOG to meet the recommendations of the meeting of the Cooperative Group Surgical Chairmen. A national intergroup protocol for intermediate thickness melanomas 1.0 to 4.0 mm was activated (EST 1683). 7. Participate in EST 5283 using autologous irradiated colon carcinoma cell vaccine with BCG and 5-FU in Dukes C colon carcinoma. 8. Continue the supervision and evaluation of the active EST 1180 adjuvant protocol in node negative breast cancer patients, chaired by our P.I. 9. To continue our activities in pilot studies in the treatment of leukemia. 10. To develop pilot studies in colorectal carcinoma, using high dose leucovorin and 5-FU.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Schools of Medicine
United States
Zip Code
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel M et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Loughran Jr, T P; Zickl, L; Olson, T L et al. (2015) Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29:886-94
Fielding, Adele K; Rowe, Jacob M; Buck, Georgina et al. (2014) UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123:843-50
Marks, David I; Moorman, Anthony V; Chilton, Lucy et al. (2013) The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica 98:945-52
Averbook, Bruce J; Lee, Sandra J; Delman, Keith A et al. (2013) Pediatric melanoma: analysis of an international registry. Cancer 119:4012-9

Showing the most recent 10 out of 59 publications